^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SENL-B19

    i
    Associations
    News

    Trials

    Company:
    SenlangBio
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825718)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Completed
    Last update posted :
    04/28/2022
    Initiation :
    01/17/2019
    Primary completion :
    09/01/2020
    Completion :
    12/01/2020
    CD19
    |
    CD19 expression
    |
    GC007F • SENL-B19
    Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells (NCT04572308)
    Phase 1
    Hebei Senlang Biotechnology Inc., Ltd.
    Completed
    Last update posted :
    06/29/2021
    Initiation :
    10/01/2020
    Primary completion :
    05/30/2021
    Completion :
    05/30/2021
    IFNG • IL6 • TNFA • IL10 • CD7
    |
    cyclophosphamide • SENL-B19 • SENL101
    Senl-h19 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04792593)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    03/11/2021
    Initiation :
    12/03/2020
    Primary completion :
    12/10/2021
    Completion :
    02/10/2022
    IFNG • IL6 • TNFA • IL10 • CD7
    |
    CD19 positive
    |
    cyclophosphamide • SENL-B19 • Senl-h19
    Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04447547)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/29/2020
    Initiation :
    06/30/2020
    Primary completion :
    08/30/2022
    Completion :
    12/30/2022
    CD19 • IFNG • IL6 • TNFA • IL10
    |
    CD19 expression
    |
    cyclophosphamide • SENL-B19 • Senl 1904B
    Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT04447573)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/29/2020
    Initiation :
    06/30/2020
    Primary completion :
    08/30/2022
    Completion :
    12/30/2022
    IFNG • IL6 • TNFA • IL10
    |
    cyclophosphamide • SENL-B19 • senl_BCMA
    Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia (NCT04546906)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/14/2020
    Initiation :
    09/01/2020
    Primary completion :
    09/01/2022
    Completion :
    12/01/2022
    IFNG • IL6 • TNFA • CD22 • IL10
    |
    CD22 positive
    |
    cyclophosphamide • SENL-B19 • Senl_22
    Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia (NCT04546893)
    Phase N/A
    Hebei Senlang Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    09/14/2020
    Initiation :
    09/01/2020
    Primary completion :
    09/01/2022
    Completion :
    12/01/2022
    IFNG • IL6 • TNFA • IL10
    |
    CD19 positive
    |
    cyclophosphamide • SENL-B19 • Senl 1904B
    A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (NCT04412174)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Not yet recruiting
    Last update posted :
    06/02/2020
    Initiation :
    06/01/2020
    Primary completion :
    12/01/2022
    Completion :
    12/01/2022
    CD22
    |
    CD22 positive • CD20 negative
    |
    GC022F • SENL-B19
    A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT04129099)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Unknown status
    Last update posted :
    05/28/2020
    Initiation :
    10/22/2019
    Primary completion :
    09/01/2020
    Completion :
    06/01/2022
    CD22
    |
    CD19 expression • CD22 expression
    |
    GC022F • SENL-B19
    A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT03825731)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Unknown status
    Last update posted :
    01/31/2019
    Initiation :
    01/17/2019
    Primary completion :
    09/16/2019
    Completion :
    09/16/2019
    CD19
    |
    CD19 expression
    |
    GC022F • SENL-B19